165 related articles for article (PubMed ID: 29607978)
21. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial.
Reid DM; Devogelaer JP; Saag K; Roux C; Lau CS; Reginster JY; Papanastasiou P; Ferreira A; Hartl F; Fashola T; Mesenbrink P; Sambrook PN;
Lancet; 2009 Apr; 373(9671):1253-63. PubMed ID: 19362675
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of minodronic acid hydrate in patients with steroid-induced osteoporosis.
Kitamura N; Shiraiwa H; Inomata H; Nozaki T; Ikumi N; Sugiyama K; Nagasawa Y; Karasawa H; Iwata M; Matsukawa Y; Takei M
Int J Rheum Dis; 2018 Apr; 21(4):813-820. PubMed ID: 26929019
[TBL] [Abstract][Full Text] [Related]
23. Clinical effects of switching from minodronate to denosumab treatment in patients with postmenopausal osteoporosis: a retrospective study.
Kobayashi M; Sawada K; Yoshimura A; Yamamoto M; Shimizu A; Shimura K; Komura N; Miyamoto M; Ishida K; Kimura T
BMC Womens Health; 2020 Mar; 20(1):48. PubMed ID: 32138724
[TBL] [Abstract][Full Text] [Related]
24. Randomized head-to-head comparison of minodronic acid and raloxifene for fracture incidence in postmenopausal Japanese women: the Japanese Osteoporosis Intervention Trial (JOINT)-04.
Uemura Y; Sone T; Tanaka S; Miyazaki T; Tsukiyama M; Taguchi A; Soen S; Mori S; Hagino H; Sugimoto T; Fukunaga M; Ohta H; Nakamura T; Orimo H; Shiraki M;
Curr Med Res Opin; 2020 Nov; 36(11):1847-1859. PubMed ID: 32870712
[TBL] [Abstract][Full Text] [Related]
25. Denosumab significantly improves bone mineral density with or without bisphosphonate pre-treatment in osteoporosis with rheumatoid arthritis : Denosumab improves bone mineral density in osteoporosis with rheumatoid arthritis.
Nakamura Y; Suzuki T; Kato H
Arch Osteoporos; 2017 Sep; 12(1):80. PubMed ID: 28936606
[TBL] [Abstract][Full Text] [Related]
26. The effects of denosumab and alendronate on glucocorticoid-induced osteoporosis in patients with glomerular disease: A randomized, controlled trial.
Iseri K; Iyoda M; Watanabe M; Matsumoto K; Sanada D; Inoue T; Tachibana S; Shibata T
PLoS One; 2018; 13(3):e0193846. PubMed ID: 29543887
[TBL] [Abstract][Full Text] [Related]
27. Four-Year Teriparatide Followed by Denosumab
Hirooka Y; Nozaki Y; Okuda S; Sugiyama M; Kinoshita K; Funauchi M; Matsumura I
Front Endocrinol (Lausanne); 2021; 12():753185. PubMed ID: 34646240
[TBL] [Abstract][Full Text] [Related]
28. Effects of discontinuing oral bisphosphonate treatments for postmenopausal osteoporosis on bone turnover markers and bone density.
Naylor KE; Bradburn M; Paggiosi MA; Gossiel F; Peel NFA; McCloskey EV; Walsh JS; Eastell R
Osteoporos Int; 2018 Jun; 29(6):1407-1417. PubMed ID: 29525970
[TBL] [Abstract][Full Text] [Related]
29. A double-blinded head-to-head trial of minodronate and alendronate in women with postmenopausal osteoporosis.
Hagino H; Nishizawa Y; Sone T; Morii H; Taketani Y; Nakamura T; Itabashi A; Mizunuma H; Ohashi Y; Shiraki M; Minamide T; Matsumoto T
Bone; 2009 Jun; 44(6):1078-84. PubMed ID: 19264155
[TBL] [Abstract][Full Text] [Related]
30. Effect on bone turnover markers of once-yearly intravenous infusion of zoledronic acid versus daily oral risedronate in patients treated with glucocorticoids.
Devogelaer JP; Sambrook P; Reid DM; Goemaere S; Ish-Shalom S; Collette J; Su G; Bucci-Rechtweg C; Papanastasiou P; Reginster JY
Rheumatology (Oxford); 2013 Jun; 52(6):1058-69. PubMed ID: 23365149
[TBL] [Abstract][Full Text] [Related]
31. Teriparatide or alendronate in glucocorticoid-induced osteoporosis.
Saag KG; Shane E; Boonen S; Marín F; Donley DW; Taylor KA; Dalsky GP; Marcus R
N Engl J Med; 2007 Nov; 357(20):2028-39. PubMed ID: 18003959
[TBL] [Abstract][Full Text] [Related]
32. Different patterns of change in bone turnover markers during treatment with bone-modifying agents for breast cancer patients with bone metastases.
Nishimukai A; Higuchi T; Ozawa H; Yanai A; Miyagawa Y; Murase K; Imamura M; Takatsuka Y; Miyoshi Y
Breast Cancer; 2017 Mar; 24(2):245-253. PubMed ID: 27040403
[TBL] [Abstract][Full Text] [Related]
33. Bisphosphonates for steroid-induced osteoporosis.
Allen CS; Yeung JH; Vandermeer B; Homik J
Cochrane Database Syst Rev; 2016 Oct; 10(10):CD001347. PubMed ID: 27706804
[TBL] [Abstract][Full Text] [Related]
34. Three years of treatment with minodronate in patients with postmenopausal osteoporosis.
Hagino H; Shiraki M; Fukunaga M; Nakano T; Takaoka K; Ohashi Y; Nakamura T; Matsumoto T
J Bone Miner Metab; 2012 Jul; 30(4):439-46. PubMed ID: 22134624
[TBL] [Abstract][Full Text] [Related]
35. Prediction of Fracture Risk From Early-Stage Bone Markers in Patients With Osteoporosis Treated With Once-Yearly Administered Zoledronic Acid.
Kasai H; Mori Y; Ose A; Shiraki M; Tanigawara Y
J Clin Pharmacol; 2021 May; 61(5):606-613. PubMed ID: 33135182
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of once-weekly teriparatide in patients with glucocorticoid-induced osteoporosis: the TOWER-GO study.
Tanaka I; Tanaka Y; Soen S; Oshima H
J Bone Miner Metab; 2021 May; 39(3):446-455. PubMed ID: 33211212
[TBL] [Abstract][Full Text] [Related]
37. Changes of bone mineral density and serum pentosidine during a 27-month follow-up of monthly minodronate in osteoporotic patients.
Ohishi T; Fujita T; Suzuki D; Nishida T; Yamamoto K; Okabayashi R; Ushirozako H; Banno T; Matsuyama Y
Endocr Res; 2017 Aug; 42(3):232-240. PubMed ID: 28318330
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and Safety of Monthly Minodronate Therapy in Postmenopausal Breast Cancer Patients Receiving Aromatase Inhibitors.
Ogata N; Toh U; Sudou T; Ogata S; Takao Y; Sugihara R; Watanabe H; Matushima S; Akagi Y
Anticancer Res; 2022 Aug; 42(8):4139-4143. PubMed ID: 35896231
[TBL] [Abstract][Full Text] [Related]
39. A review of minodronic acid hydrate for the treatment of osteoporosis.
Tanishima S; Morio Y
Clin Interv Aging; 2013; 8():185-9. PubMed ID: 23440003
[TBL] [Abstract][Full Text] [Related]
40. A comparative study of the effects of daily minodronate and weekly alendronate on upper gastrointestinal symptoms, bone resorption, and back pain in postmenopausal osteoporosis patients.
Yoshioka T; Okimoto N; Okamoto K; Sakai A
J Bone Miner Metab; 2013 Mar; 31(2):153-60. PubMed ID: 23076293
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
